Memorandum of Understanding with The University of Texas MD Anderson Cancer Center

Current report no. 55/2025

Drafting date: 17.11.2025

Subject: Memorandum of Understanding with The University of Texas MD Anderson Cancer Center 

Legal basis: Article 17(1) MAR - confidential information.

The Management Board of Captor Therapeutics S.A., headquartered in Wrocław (the “Company”), hereby presents the content of a joint announcement regarding the signing of a Memorandum of Understanding with the MD Anderson Cancer Centre (MD Anderson Cancer Centre, MDACC) at the University of Texas, under which MDACC will conduct a clinical trial in the form of an Investigator-Initiated Trial, also known as an Academic Clinical Trial or Investigator-Sponsored Trial.

The content of the announcement agreed with MD Andreson

Captor Therapeutics S.A. (WSE: CTX), an innovative biopharmaceutical company, today announced it has entered into a Memorandum of Understanding with The University of Texas MD Anderson Cancer Center to support an Investigator-Initiated Trial (IIT) for Captor's lead asset – an MCL-1 protein degrader for the treatment of hematological malignancies. 

The clinical trial builds upon preclinical research conducted at MD Anderson by Michael Andreeff, M.D., Ph.D., professor of Leukemia, and Bing Carter, Ph.D., professor of Leukemia, in collaboration with Captor. Amongst the findings, the clinical candidate, CT-03p, was shown to decrease MCL-1 protein levels, induce death of leukemia cells, and synergize with BCL-2 inhibition in cells resistant to venetoclax, CT-03p, or both. Updated results from this research will be presented at the American Society of Hematology Annual Meeting December 2025.  

Abhishek Maiti, M.D., assistant professor of Leukemia at MD Anderson, will serve as the trial’s principal investigator.